| COVID-19 |
1 |
1 |
| Antidepressant drug |
0 |
0.99 |
| Depression |
0 |
0.75 |
| Washington |
0 |
0.32 |
| Monoamine Oxidase Inhibitor |
0 |
0.23 |
| Selective Serotonin-Reuptake Inhibitors |
0 |
0.23 |
| Biologic Therapy |
0 |
0.22 |
| California |
0 |
0.21 |
| Hospital |
0 |
0.21 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.21 |
| Pandemic |
0 |
0.21 |
| Platelet Count |
0 |
0.21 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.21 |
| HIV Infection |
0 |
0.2 |
| Patient Safety |
0 |
0.2 |
| Obsessive-Compulsive Disorder |
0 |
0.16 |
| Vaccines |
0 |
0.16 |
| Thrombus |
0 |
0.15 |
| Treatment Guidelines |
0 |
0.15 |
| Electronic Health Record (EHR) and Healthcare Technology |
0 |
0.13 |
| Thromboembolism |
0 |
0.13 |
| Adverse Effects |
0 |
0.11 |
| Anticoagulation Therapy |
0 |
0.11 |
| Antipsychotics |
0 |
0.11 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.11 |
| Blood |
0 |
0.11 |
| Brachial |
0 |
0.11 |
| Child |
0 |
0.11 |
| Clinical Guidelines |
0 |
0.11 |
| Electronic Medical Record |
0 |
0.11 |
| Fatigue |
0 |
0.11 |
| Food and Drug Administration (FDA) |
0 |
0.11 |
| Health Care Quality, Access, and Evaluation |
0 |
0.11 |
| Intubation |
0 |
0.11 |
| Massachusetts |
0 |
0.11 |
| Minnesota |
0 |
0.11 |
| Monoclonal Antibody |
0 |
0.11 |
| Nausea |
0 |
0.11 |
| Outbreak |
0 |
0.11 |
| Outpatient Clinic |
0 |
0.11 |
| Peer Review |
0 |
0.11 |
| Politics |
0 |
0.11 |
| Receptors |
0 |
0.11 |
| Social Media |
0 |
0.11 |
| Steroids |
0 |
0.11 |
| Stress |
0 |
0.11 |
| UK Site Content |
0 |
0.11 |
| Health Care Reform |
0 |
0.09 |
| Social Determinants of Health |
0 |
0.05 |